Patents by Inventor Angelo Gámez Pozo

Angelo Gámez Pozo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same
    Patent number: 11401556
    Abstract: A prognostic method, and a kit, for determining the risk of relapse of renal cancer of the clear cell renal carcinoma type, stages I and II, in a human subject; comprised of: (a) determining, in a tumor sample (biopsy) from the human subject, the levels of expression of the microRNAs hsa-miR-223, hsa-miR-103, hsa-miR-107, hsa-miR-425, hsa-miR-340, hsa-miR-130b, hsa-miR-652, hsa-miR-214, and hsa-miR-204; (b) determining a value which depends on the levels of expression of the microRNAs; and (c) determining the risk of relapse in renal cancer of the clear cell renal carcinoma type, in stages I and II, in the said human subject, by comparing the value obtained in step (b) with a cut-off value.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: August 2, 2022
    Assignees: FUNDACIÔN PARA LA INVESTIGACIÔN BIOMEDICA DEL HOSPITAL 12 DE OCTUBRE, FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PAZ (FIBHULP)
    Inventors: Natalia Miranda Utrera, Felipe Villacampa Aubá, Daniel Castellano, Juan Angel Fresno Vara, Angelo Gámez Pozo
  • PROGNOSTIC METHOD FOR DETERMINING THE RISK OF RELAPSE IN RENAL CANCER PATIENTS WITH A CLEAR CELL TYPE OF RENAL CARCINOMA, STAGES I AND II, AND KIT FOR SAME
    Publication number: 20180346990
    Abstract: A prognostic method, and a kit, for determining the risk of relapse of renal cancer of the clear cell renal carcinoma type, stages I and II, in a human subject; comprised of: (a) determining, in a tumor sample (biopsy) from the human subject, the levels of expression of the microRNAs hsa-miR-223, hsa-miR-103, hsa-miR-107, hsa-miR-425, hsa-miR-340, hsa-miR-130b, hsa-miR-652, hsa-miR-214, and hsa-miR-204; (b) determining a value which depends on the levels of expression of the microRNAs; and (c) determining the risk of relapse in renal cancer of the clear cell renal carcinoma type, in stages I and II, in the said human subject, by comparing the value obtained in step (b) with a cut-off value.
    Type: Application
    Filed: September 23, 2016
    Publication date: December 6, 2018
    Inventors: Natalia Miranda Utrera, Felipe Villacampa Aubá, Daniel Castellano, Juan Angel Fresno Vara, Angelo Gámez Pozo